A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction
Naomi Fischer, Elad Moisseiev, Michael Waisbourd, Michaella Goldstein, Anat Loewenstein Department of Ophthalmology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Purpose: The study reported here investigated the rates of systemic serious adverse events...
Guardado en:
Autores principales: | Fischer N, Moisseiev E, Waisbourd M, Goldstein M, Loewenstein A |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9011acd3bb744c8a90fd4a430571cad7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis.
por: Wei Wang, et al.
Publicado: (2014) -
Intravitreal bevacizumab injections for diabetic macular edema – predictors of response: a retrospective study
por: Joshi L, et al.
Publicado: (2016) -
Case of endophthalmitis following intravitreal injections of bevacizumab
por: Shinya Komori, et al.
Publicado: (2010) -
Is monthly retreatment with intravitreal bevacizumab (Avastin®) necessary in neovascular age-related macular degeneration?
por: Nicola G Ghazi, et al.
Publicado: (2010) -
Comparison of single injection and three monthly injections of intravitreal bevacizumab for macular edema associated with branch retinal vein occlusion
por: Ito Y, et al.
Publicado: (2015)